Avantax Advisory Services’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.34M | Buy |
2,551
+732
| +40% | +$384K | 0.01% | 995 |
|
|
2025
Q1 | $1.15M | Buy |
1,819
+195
| +12% | +$124K | 0.01% | 1011 |
|
|
2024
Q4 | $1.16M | Buy |
1,624
+404
| +33% | +$288K | 0.01% | 973 |
|
|
2024
Q3 | $1.28M | Sell |
1,220
-339
| -22% | -$356K | 0.01% | 901 |
|
|
2024
Q2 | $1.64M | Buy |
1,559
+568
| +57% | +$597K | 0.01% | 742 |
|
|
2024
Q1 | $954K | Sell |
991
-10
| -1% | -$9.63K | 0.01% | 768 |
|
|
2023
Q4 | $879K | Buy |
1,001
+187
| +23% | +$164K | 0.01% | 757 |
|
|
2023
Q3 | $670K | Buy |
814
+81
| +11% | +$66.7K | 0.01% | 826 |
|
|
2023
Q2 | $527K | Buy |
733
+391
| +114% | +$281K | 0.01% | 928 |
|
|
2023
Q1 | $281K | Buy |
342
+8
| +2% | +$6.57K | ﹤0.01% | 1183 |
|
|
2022
Q4 | $241K | Buy |
+334
| New | +$241K | ﹤0.01% | 1223 |
|
|
2020
Q4 | – | Sell |
-857
| Closed | -$479K | – | 1267 |
|
|
2020
Q3 | $479K | Buy |
+857
| New | +$479K | 0.01% | 804 |
|